Dezocine inhibits cell proliferation, migration, and invasion by targeting CRABP2 in ovarian cancer-Reference-Cited by-同舟云学术

Dezocine inhibits cell proliferation, migration, and invasion by targeting CRABP2 in ovarian cancer

Published:2022-01-01 Issue:1 Volume:17 Page:2052-2061
ISSN:2391-5463
Container-title:Open Medicine
language:en
Short-container-title:

Author:

Zhang Chuanfeng¹,Pan Ruirui¹,Ma Shuangshuang¹,Xu Shoucai¹,Wang Baosheng²

Affiliation:

1. Department of Anesthesiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences , Jinan 250117 , Shandong , China

2. Department of Anesthesiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences , No.440 Jiyan Road , Jinan 250117 , Shandong , China

Abstract

Abstract Previous studies have shown that some anesthesia drugs can inhibit tumor growth and metastasis. As a clinical anesthetic drug, dezocine has been reported to play an important role in immune function. However, the effects of dezocine on ovarian cancer cell growth and metastasis are not fully understood. In this study, we found that dezocine dose-dependently inhibited the viability of ES-2 and SKOV3 cells. Dezocine suppressed the migration and invasion abilities of ovarian cancer cells, and promoted apoptosis. Moreover, the Akt/mTOR signaling pathway was also inhibited by dezocine. Furthermore, mechanism study showed that dezocine could significantly inhibit the expression of CRABP2, and CRABP2 overexpression reversed the inhibitory effects of dezocine on ovarian cancer cell proliferation and migration. In conclusion, dezocine has significant anti-tumor effects on the growth and metastatic potential of ovarian cancer cells, and CRABP2 functions as a downstream effector of dezocine.

Publisher

Walter de Gruyter GmbH

Subject

General Medicine

Link

https://www.degruyter.com/document/doi/10.1515/med-2022-0541/pdf

Reference36 articles.

1. Smolle E, Taucher V, Petru E, Haybaeck J. Targeted treatment of ovarian cancer – the multiple – kinase – inhibitor sorafenib as a potential option. Anticancer Res. 2014;34(4):1519–30.

2. Harter P, Gershenson D, Lhomme C, Lecuru F, Ledermann J, Provencher DM, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors). Int J Gynecol Cancer. 2014;24(9 Suppl 3):S5–8. 10.1097/igc.0000000000000282.

3. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14:9–32.

4. Wang V, Cheng L, Ming L, William W, Deborah B, Yuk-Fu W, et al. Ovarian cancer is a heterogeneous disease. Cancer Genet Cytogenet. 2005;161(2):170–3.

5. Fishman DA, Cohen L, Blank SV, Shulman L, Singh D, Bozorgi K, et al. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol. 2005;192(4):1214–21. 10.1016/j.ajog.2005.01.041. Discussion 21-2.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the cellular and molecular differences between ovarian clear cell carcinoma and high-grade serous carcinoma using single-cell RNA sequencing and GEO gene expression signatures;Cell & Bioscience;2023-07-31

2. Dezocine inhibits proliferation as well as migration of endometrial carcinoma in vitro;European Journal of Gynaecological Oncology;2023